Acoramidis Hydrochloride Patent Expiration
Acoramidis Hydrochloride was first introduced by Bridgebio Pharma Inc
Acoramidis Hydrochloride Patents
Given below is the list of patents protecting Acoramidis Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Attruby | US11260047 | Formulations of AG10 | Aug 16, 2039 | Bridgebio Pharma |
| Attruby | US12005043 | Formulations of AG10 | Aug 16, 2039 | Bridgebio Pharma |
| Attruby | US11058668 | Methods of treating TTR amyloidosis using AG10 | Mar 22, 2039 | Bridgebio Pharma |
| Attruby | US12070449 | Methods of treating TTR amyloidosis using AG10 | Mar 22, 2039 | Bridgebio Pharma |
| Attruby | US10513497 | Process for preparing AG-10, its intermediates, and salts thereof | Feb 16, 2038 | Bridgebio Pharma |
| Attruby | US11919865 | Processes for preparing AG-10, its intermediates, and salts thereof | Feb 16, 2038 | Bridgebio Pharma |
| Attruby | US9913826 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | Mar 14, 2033 | Bridgebio Pharma |
| Attruby | US10398681 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | May 05, 2031 | Bridgebio Pharma |
| Attruby | US10842777 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | May 05, 2031 | Bridgebio Pharma |
| Attruby | US8877795 | Identification of stabilizers of multimeric proteins | May 05, 2031 | Bridgebio Pharma |
| Attruby | US9169214 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | May 05, 2031 | Bridgebio Pharma |
| Attruby | US9642838 | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | May 05, 2031 | Bridgebio Pharma |
Acoramidis Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List